Skip to main content

Search

Show all results for

Home

Person

Jérémy Vuilleumier

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (8)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Gd3+-Functionalized Lithium Niobate Nanoparticles for Dual Multiphoton and Magnetic Resonance Bioimaging

Marinella Mazzanti, Sandrine Gerber, Anne-Sophie Chauvin, Katarzyna Pierzchala, Ileana Ozana Jelescu, Jérémy Vuilleumier, Raphaël Jovita De Matos, Laura Camille Louise Nicolle, Adrian Stefan Gheata, Dario Diviani

Harmonic nanoparticles (HNPs) have emerged as appealing exogenous probes for optical bioimaging due to their distinctive features such as long-term photostability and spectral flexibility, allowing multiphoton excitation in the classical (NIR-I) and extend ...

2022

Photoresponsive Nanocarriers Based on Lithium Niobate Nanoparticles for Harmonic Imaging and On-Demand Release of Anticancer Chemotherapeutics

Sandrine Gerber, Jérémy Vuilleumier, Adrian Stefan Gheata, Dario Diviani, Luigi Bonacina, Simon Kaiser

Nanoparticle-based drug delivery systems have the potential for increasing the efficiency of chemotherapeutics by enhancing the drug accumulation at specific target sites, therebyreducing adverse side effects and mitigating patient acquired resistance. In ...

2022

Photocontrolled release of the anticancer drug chlorambucil with caged harmonic nanoparticles

Sandrine Gerber, Jean-Pierre Wolf, Jérémy Vuilleumier, Raphaël Jovita De Matos, Luigi Bonacina

While chemotherapy is one of the most used treatments in oncology, the systemic administration of chemotherapeutics generally results in undesired damages to healthy tissues and cells, side effects such as severe nausea and leukopenia, and reduced efficacy ...

Wiley-VHCA AG2020